daniel lavanchy
daniel lavanchy
healthcare consultant
Verified email at alumnibasel.ch
TitleCited byYear
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
D Lavanchy
Journal of viral hepatitis 11 (2), 97-107, 2004
32132004
The global burden of hepatitis C
D Lavanchy
Liver international 29, 74-81, 2009
17022009
Evolving epidemiology of hepatitis C virus
D Lavanchy
Clinical Microbiology and Infection 17 (2), 107-115, 2011
15272011
The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt
C Frank, MK Mohamed, GT Strickland, D Lavanchy, RR Arthur, ...
The Lancet 355 (9207), 887-891, 2000
13682000
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ...
The Lancet Gastroenterology & Hepatology 2 (3), 161-176, 2017
7482017
EASL international consensus conference on hepatitis B 13-14 September, 2002 Geneva, Switzerland Consensus statement (Long version)
R De Franchis, A Hadengue, G Lau, D Lavanchy, A Lok, N McIntyre, ...
Journal of Hepatology 39 (SUPPL. 1), 2003
656*2003
EASL international consensus conference on hepatitis B 13-14 September, 2002 Geneva, Switzerland Consensus statement (Long version)
R De Franchis, A Hadengue, G Lau, D Lavanchy, A Lok, N McIntyre, ...
Journal of Hepatology 39 (SUPPL. 1), 2003
656*2003
Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention
D Lavanchy
Journal of clinical virology 34, S1-S3, 2005
6322005
EASL international consensus conference on hepatitis B 13-14 September, 2002 Geneva, Switzerland Consensus statement (Long version)
R De Franchis, A Hadengue, G Lau, D Lavanchy, A Lok, N McIntyre, ...
Journal of Hepatology 39 (SUPPL. 1), 2003
5232003
EASL international consensus conference on hepatitis B 13-14 September, 2002 Geneva, Switzerland Consensus statement (Long version)
R De Franchis, A Hadengue, G Lau, D Lavanchy, A Lok, N McIntyre, ...
Journal of Hepatology 39 (SUPPL. 1), 2003
5232003
Global burden of disease (GBD) for hepatitis C
Global Burden of Hepatitis C Working Group
The Journal of Clinical Pharmacology 44 (1), 20-29, 2004
4292004
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ...
Journal of viral hepatitis 21, 34-59, 2014
4152014
Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium
World Health Organization
J Viral Hepat 6, 35-47, 1999
3371999
Historical epidemiology of hepatitis C virus (HCV) in selected countries
P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ...
Journal of viral hepatitis 21, 5-33, 2014
2962014
Strategies to manage hepatitis C virus (HCV) disease burden
H Wedemeyer, AS Duberg, M Buti, WM Rosenberg, S Frankova, G Esmat, ...
Journal of viral hepatitis 21, 60-89, 2014
2132014
Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants
D FitzSimons, G François, A Hall, B McMahon, A Meheus, A Zanetti, ...
Vaccine 23 (32), 4158-4166, 2005
1622005
WHO report on global surveillance of epidemic-prone infectious diseases
World Health Organization
World Health Organization, 2000
1612000
EASL international consensus conference on hepatitis B. 13–14 September, 2002: Geneva, Switzerland. Consensus statement (short version)
E Jury
J Hepatol 38 (4), 533-540, 2003
1562003
Chronic viral hepatitis as a public health issue in the world
D Lavanchy
Best practice & research Clinical gastroenterology 22 (6), 991-1008, 2008
1352008
Seroprevalence of hepatitis E virus in Switzerland
D Lavanchy, B Morel, PC Frei
The Lancet 344 (8924), 747-748, 1994
1331994
The system can't perform the operation now. Try again later.
Articles 1–20